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ABSTRACT Semiconductor quantum dots (QDs) are a new class of fluorophores with unique physical and chemi-
cal properties, which allow to appreciably expand the possibilities for the current methods of fluorescent imag-
ing and optical diagnostics. Here we discuss the prospects of QD application for molecular diagnostics of tumors 
ranging from cancer-specific marker detection on microplates to non-invasive tumor imaging in vivo. We also 
point out the essential problems that require resolution in order to clinically promote QD, and we indicate in-
novative approaches to oncology which are implementable using QD.
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ABBREVIATIONS AFP – alpha-fetoprotein; EGF – epidermal growth factor; EGFR - epidermal growth factor 
receptor; ELISA – enzyme-linked immunosorbent assay; HER2/neu - human epidermal growth factor receptor 
2/neu; IGF1R – type 1 insulin-like growth factor receptor; IHC – immunohistochemistry; MAA – mercaptoacetic 
acid; QDs – quantum dots; PEG – polyethylene glycol; scFv – single-chain variable antibody fragment; PSCA – 
prostate stem cell antigen; PSMA – prostate-specific membrane antigen; RES –reticuloendothelial system; ROS – 
reactive oxygen species.
INTRODUCTION
In recent biomedical studies, much attention has been 
paid to the search for new methods of noninvasive 
imaging of the internal structure of biological objects. 
Instruments with a high spatial resolution have been 
designed, and, consequently, optical methods for in-
vestigation are gaining widespread use. One of the most 
demonstrable and informative methods among these is 
the fluorescent diagnostics of pathological foci directly 
in the organism.
A considerable  portion of the methods being devel-
oped are directed toward imaging tumors, tissues and 
organs; studying the molecular structure of tumor cells 
by auto-fluorescence registration; or by specific stain-
ing of the objects under observation with fluorescent 
contrasting dyes.  Methods such as these enable us not 
only to localize a tumor in the organism, but also to esti-
mate the level of expression of various proteins, as well 
as the activity of individual cells and the processes that 
have an impact on tumor behavior and its response to 
the action of therapeutic agents.
In modern methods of diagnostics, special demands 
are placed on the contrast agents used. Fluorophores 
must possess the following properties: small dimensions 
(1–10 nm); sufficient brightness and a high quantum 
yield; it is necessary that their excitation and fluores-
cence in the spectral range correspond to optimum 
penetration into biological tissues; and chemical sta-
bility, photostability, and biocompatibility (stability in 
biological media and nontoxicity). Moreover, frequent-
ly in order to perform biological studies, these fluoro-
phores need to be conjugated with different targeting 
molecules, so that they can be delivered to particular 
targets (proteins, compartments, and cells). The conju-
gates need to specifically interact with the target and 
do so in a stable manner, whilst possessing a low level 
of nonspecific binding.
Fluorescent semiconductor nanocrystals, so-called 
quantum dots (QDs), are a relatively novel class of 
fluorophores with unique optical and physicochemi-
cal properties, atypical of other fluorescent dyes. Two 
major classes of fluorophores have been convention-
ally used for diagnostics: organic dyes and fluorescent 
proteins [1]. These fluorophores were first used in biol-
ogy and medicine and have subsequently evolved sig-
nificantly. At this point, a large variety of organic dyes 
with a small molecular weight and fluorescent proteins,   
characterized by high brightness, good quantum yield 
and emission over the entire spectral region from blue 
to the near-infrared (IR) region, have been designed 
[2, 3]. However, some of the properties of these fluoro-
phores (in particular, broad emission spectrum and low 
photobleaching thresholds) still limit their effective-
ness in such types of studies as long-term imaging and 
‘multiplexing’ (simultaneous detection of multiple sig-
nals) without an additional complex of instrumentation 
and processing [4].
QDs possess a number of physicochemical features 
that open wider possibilities in comparison with con-
ventionally used fluorescent labels, making them par-
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ticularly attractive for use in various biological experi-
ments [5, 6].
This review will summarize how QDs can be used for 
studying the molecular mechanisms of the processes 
that occur in tumor cells and for both in vitro and in 
vivo tumor diagnostics.
1. QD FEATURES PROVIDING ADVANTAGES 
WHEN USING THEM IN BIOMEDICAL STUDIES
Quantum dots are almost spherical nanocrystals 
1–10 nm in diameter, consisting of a small number 
of atoms (500–10,000) of semiconductor materials of 
groups II–VI (e.g., CdSe, CdTe, CdS, and ZnSe) or 
groups III–V (e.g., InP and InAs) of Mendeleev’s pe-
riodic table. The term “dot” mainly characterizes the 
extremely small dimension of these objects; while the 
adjective “quantum” describes the fact that their be-
havior and properties are described to a significant 
extent by quantum mechanics, rather than classical 
mechanics. The decrease in the particle size of the 
compound to a value smaller than the exciton Bohr 
radius (e.g., for spherical СdSe particles this diam -
eter is less than 6 nm) results in that the properties of 
the compound are determined not as much by their 
chemical composition as by their particle size. In light 
of this, semiconductor nanocrystals are characterized 
by their unique optical characteristics and physico-
chemical properties that distinguish them favorably 
from other fluorophores that are conventionally used 
in biology [7].
QDs possess a high molar extinction coefficient 
(higher than that of organic dyes by a factor of 10–
100) and a high quantum yield (up to 90%), which 
provides to these fluorophores exceptional bright-
ness. QDs are characterized by a broad absorption 
spectrum, a considerable Stokes shift, and a narrow 
and symmetrical (without a “tail” in the red region) 
fluorescence spectrum (peak width ~25–40 nm). In 
this regard, the emission wavelength is core size-
tunable, enabling us to create a wide range of various 
QDs fluorescing within a spectral range from UV to 
IR (400–2,000 nm), using the same materials and the 
same procedures (Fig. 1). Furthermore, the broad ex-
citation spectrum typical of these nanoparticles (QDs 
can be excited by light at any wavelength smaller than 
their fluorescence wavelength) allows to excite a mix-
ture of different QDs at one wavelength that is con-
siderably remote (> 100 nm) from their fluorescence 
wavelengths [9]. Such properties of QDs significantly 
increase their potential use in multicolor labeling and 
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Fig. 1. Representative QD core materials scaled as a function of their emission wavelength superimposed over the 
spectrum. Representative areas of biological interest are also presented corresponding to the pertinent emission, 
highlighting how most biological usage falls in the visible – near-infrared region. Reprinted by permission from Macmillan 
Publishers Ltd.: [Nature Materials] (Medintz I.L., Uyeda H.T., Goldman E.R., Mattoussi H. Nat Mater. 2005 4:435-446), 
copyright (2005).REVIEWS
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the simultaneous identification of different biological 
objects, in comparison with other dyes [6].
High resistance to photobleaching (that is higher 
than that of organic fluorophores by a factor of 100–
1,000) and an exceptional stability towards photo- and 
chemical degradation [7, 10], which is typical of fluores-
cent semiconductor nanocrystals, makes it possible for 
us to use them in long-term experiments on real-time 
imaging of the processes occurring inside a cell (e.g., 
endocytosis) [11] or translocation of individual recep-
tor molecules along the living cellular surface and for 
staining the samples that require long-term storage 
[13].
A more detailed description of the physicochemical 
properties of QDs important for their biological appli-
cation, and a comparative evaluation of their use and 
that of other fluorophores in biomedical studies, can be 
found in reviews [4–6].
Physicochemical and optical properties and the fea-
tures of QDs directly depend on the method of their 
synthesis. This wide field (not an issue for this review) 
is still under development. It is increasing the number 
of QDs used in biomedical studies and enhancing their 
properties (ref. reviews [4, 5]).
Until recently, two types of water-soluble mono-
disperse QDs had been in use in biology: the so-called 
bioinert nanocrystals and nanocrystals conjugated to 
various biological molecules in order to add certain spe-
cificity to them.
Bioinert QDs find application as nonspecific con-
trast agents for cell staining due to endocytosis, for the 
contrasting of blood vessels and lymph nodes, and for 
studying biodistribution, toxicity, and in vivo passive 
delivery of nanoparticles into animal tumors. Water-
soluble QDs modified with hydrophilic thiols [14] and 
encapsulated by silicon or amphiphilic polymers [16] 
are frequently used as such bioinert particles. Such 
particles are typically coated with a layer of inert mol-
ecules, in order to reduce the nonspecific binding; the 
manufacturers of commercial QDs usually use polyeth-
ylene glycol (PEG) for this purpose.
2. TARGETING OF QDS TO TUMOR CELLS
It is a common requirement when using QDs as fluor-
ophores for tumor imaging that they bind to various 
targeting molecules, thus ensuring the selective deliv-
ery of QDs to tumor cells and their components. The 
specificity of labeling is provided by the selection of a 
target that optimally suits each particular case and the 
corresponding targeting molecule.
The receptor part of signal proteins that are overex-
pressed on tumor cell membranes is used most often as 
a specific target. The level of expression of these cel-
lular molecular oncomarkers, determined directly in 
the tumor tissue, characterizes the molecular profile 
of each individual tumor and is used to determine the 
immune status of the tumor and the individualization 
of therapeutic treatment [17].
Antibodies and their fragments, ligands of specific 
receptors localized on the tumor cell surface, small mol-
ecules (such as peptides and aptamers) with specific 
affinity for some of the oncomarkers are used as a tar-
geting module, which provides the selective delivery of 
QDs to tumor cells and their components, depending on 
the aims and objects of the study.
2.1 Targeting agents
Immynoglobulin (Ig) molecules have been known for a 
long time, as they are widely used as efficient target-
ing modules for the specific delivery of diagnostic and 
therapeutic agents both in vitro at the cell and tissue 
level and in vivo at the whole body level. As early as in 
one of the first studies devoted to using QDs for biologi-
cal investigations,  the potential to obtain complexes of 
QDs with IgG molecules and the ability of the result-
ing complexes to bind to specific antispecies polyclonal 
antibodies and to form precipitates in the solution were 
illustrated [14]. Later, such complexes were used for 
the labeling of particular molecules located in various 
cell compartments (on the membrane surface, in cyto-
plasm, and in the cellular nucleus) [16].
Regardless of the wide distribution of full-size an-
tibodies in diagnostic systems in vitro, their applica-
tion as targeting agents in vivo usually requires the 
elimination of their effector functions and a radical 
modification of physicochemical properties [18]. Anti-
bodies of scFv format are those that best meet these 
requirements [19, 20]. These small antibody fragments 
do not contain a constant domain. Although this fact 
has no effect on their targeting properties, it reduces 
the possibility of the side effects caused by the interac-
tion between the constant domains and receptors of the 
cells of the immune system and proteins of the com-
plement system [21]. scFv antibodies against  surface 
oncomarkers are widely used as targeting modules for 
the fluorescent imaging of tumor cells and delivery of 
therapeutic agents to them [22–24].
At the Nie laboratory, it was demonstrated that QDs 
conjugated to targeting mini antibodies scFv could be 
used for tumor imaging, including in vivo imaging. Ac-
cumulation by tumor cells and efficient internalization 
of QDs conjugated to a human anti-EGFR-antibody of 
the scFv format were observed after their intravenous 
injection into a human pancreatic bearing mouse [25].
The major bottleneck of scFv antibodies as targeting 
agents is their monovalence, since monovalent bind-
ing to an antigen on the cell surface does not ensure 
the long-term retention of the antibody and results in 32 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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its rapid dissociation [26, 27]. Meanwhile, the typically 
large surface area of QDs makes it possible to attach 
several scFv molecules to each nanoparticle and cre-
ate unique multivalent constructions with enhanced 
properties [28].
Peptides are used as targeting molecules in order to 
perform specific recognition of certain proteins, with 
the purpose of imaging cells and their components [29]. 
The application of this approach in the design of target-
ed QDs was first demonstrated for short recombinant 
peptides that were capable of specific recognition of 
integrin in human neiroblastoma studies [30]. Later, 
it was proven that this approach could also be used in 
the specific labeling of the cells of lung endothelium, 
brain endothelium, and human breast carcinoma both 
in vitro and in living cells [31]. Arginyl-glycyl-aspartic 
acid (RGD peptide) capable of recognizing integrin has 
been noted as a good alternative targeting agent for the 
fluorescing in the IR range QDs during in vivo imaging 
of different tumors in the mouse organism [32]. 
Another promising targeting agent for the delivery 
of QDs to tumor cells is aptamers; the specially de -
signed oligonucleotides capable of recognizing certain 
proteins and cell components and binding to them with 
high specificity. Various aptamer-based conjugates 
have been successfully used for cell imaging and recog-
nition, biomarker detection, etc. [33]. Conjugates of QDs 
with the aptamer specific to the PSMA cancer marker 
selectively stained immobilized and living prostate tu-
mor LNCaP cells and the same cells in a model medi-
um of collagen matrix [34]. It was shown that the use 
of aptamers as a targeting agent for imaging prostate 
tumor cells using QDs was equally efficient as using 
QDs conjugated to anti-PSMA-antibodies, but consid-
erably less expensive [35]. QD-aptamer conjugates can 
be used in parallel with other targeting agents, such as 
peptides, for the simultaneous imaging of several on-
comarkers [36]. Moreover, the preparation of biotin-
conjugated aptamers, which have the ability to bind 
to any streptavidin-conjugated QDs, provides the pos-
sibility to create universal reagents for the two-stage 
delivery of QDs to tumor cells [33].
2.2 Methods for binding targeting agents to QDs
In contemporary practice, two major approaches to 
binding the targeting molecules to QDs are used: direct 
binding (typically covalent) of protein molecules to ac-
tive groups on the QD surface and adaptor-mediated 
binding (Fig. 2).
Usually, protein molecules are bound directly to the 
semiconductor part of a nanocrystal (via the SH group 
or by metal-affine coordination of histidine residues 
with the zinc atoms of a nanocrystal shell) or to its hy-
drophilic coating (by conjugation with carboxyl, amine, 
scFv antibody
Barnase
Barstar
Streptavidin
Biotin
Aptamer
Full-size antibody
Fig. 2. Design of a current quantum dot for biomedical application. (1) –fluorescent core (usually CdSe or CdTe);  
(2) - protective shell (usually ZnS); (3) – polymer coating to provide colloidal stability, and direct linkage to biologically 
active molecules, (4) – PEG, (5) – targeting molecules joined with QD directly or through biotin-streptavidin (6) and 
barnase-barstar (7) adaptor systems.REVIEWS
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and thiol groups using special catalysts; via electrostatic 
interaction). These methods were thoroughly described 
in the reviews [5, 37].
The surface area of a nanocrystal is appreciably 
large and is accessible for the binding of several bio-
logical molecules.  A range of 2 to 5 protein molecules 
and more than 50 small molecules (oligonucleotides or 
peptides) can be bound to one nanoparticle 4 nm in di-
ameter [38]. It should be noted that the reactivity of 
certain types of biological molecules after direct con-
jugation with nanocrystals can vary considerably. In 
particular, although antibodies retain their specificity 
after conjugation, they lose their affinity considerably 
[39]. Moreover, direct conjugation of QDs with antibod-
ies requires that the antibody activity in each new con-
jugate be checked.
The use of so-called “self-assembling adaptors” 
(small adhesive molecules that bind to each other with 
high efficiency and specificity but do not form ho -
modimers) is a more promising approach to QD binding 
to antibodies. The formation of complexes with these 
small molecules has no considerable effect on antibody 
affinity and allows us to simply prepare various com-
binations of antibodies with different specificities to 
QDs that fluoresce in different ranges, without any 
additional modifications. Heterodimerization modules 
that were previously designed for the preparation of 
recombinant bispecific and multivalent antibodies and 
for two-stage delivery of therapeutic agents to the tu-
mor are used as adaptor molecules to bind QDs to an-
tibodies.
The streptavidin–biotin system is the most well-
known and broadly used system among these modules; 
it possesses a high binding affinity Ka ~ 10-14 – 10-15 М 
[40]. Streptavidin is attached to QDs covalently or via 
electrostatic interactions, which allows them to bind to 
biotin-conjugated targeting agents. Streptavidin-con-
jugated QDs were first used for imaging of the tumor 
marker HER2/neu on the surface of human breast tu-
mor SKBR-3 cells through biotin-conjugated anti-hu-
man secondary antibodies and humanized anti-HER2/
neu antibodies [16]. A similar three-stage system was 
used for binding QDs to antibody fragments specific 
to glycyn receptors on a neuron membrane, making it 
possible to observe the motion of individual receptors 
in living neurons [41]. The three-stage system based 
on the biotin–streptavidin affine pair (primary anti-
bodies; biotinilated secondary antibodies; streptavidin-
conjugated quantum dots) allows for the use of single 
streptavidin-conjugated quantum dots for the imaging 
of a number of various targets without any additional 
modification, since the labeling specificity is deter-
mined by the corresponding primary and biotinilated 
secondary antibodies.
By using primary antibodies that bind to QDs via a 
biotin–streptavidin bridge [11], the number of stages 
in the labeling process can be reduced to two. This ap-
proach is not only used for antibodies, but also for many 
other targeting agents. Thus, QDs conjugated with an 
integrin-recognizing peptide via a biotine–streptavidin 
module have been successfully used for labeling the 
αν-subunit of integrin in human neuroblastoma cells 
SK-N-SH [27].
 Because of its universal nature, the streptavidin–
biotin system is now widely used in certain types of im-
mune diagnostic investigations that use QDs. Strepta-
vidin-conjugated QDs and biotin-conjugated antibodies 
became commercially available recently (e.g., see www.
invitrogen.com). However, it is important to note that 
the application of this system to create site-directed 
fluorophores for tumor imaging in a human organism in 
vivo is restricted by the presence of a large quantity of 
endogenous biotin, which can compete with biotinilated 
components, thus reducing the labeling efficiency.
In order to prepare antibody-conjugated QDs, we 
propose the use of a barnase–barstar adaptor mod-
ule, which has shown good results in the preparation 
of heterodimeric mini-antibodies and their fluorescent 
derivatives [26, 42, 43]. This adaptor module is based on 
the ability of ribonuclease barnase from Bacillus amy-
loliquefaciens to form a very stable complex (Kd ~ 10-14 
М) with its natural protein inhibitor, barstar [26].
Since the binding regions of barnase and barstar are 
localized outside their N- and C-terminal parts, each 
of these proteins is accessible for fusion with scFv an-
tibody fragments. Meanwhile, the binding efficiency 
of module components is retained. The small dimen-
sions of barnase and barstar (110 and 89 a.a., respec-
tively), stability, good solubility, and stability towards 
proteases allow to produce appreciable quantities of the 
desired chimeric proteins in bacterial producers. More-
over, barnase, within recombinant proteins, serves 
as an intramolecular chaperone, ensuring the correct 
folding of recombinant proteins, which is particularly 
important when designing structures with targeting 
antibodies [44].
The small dimensions and extreme stability over 
a wide range of conditions make it possible to easily 
form conjugates of both barnase and barstar with ac-
tive groups on the QD surface. It was also found that 
the conjugation of QDs with barstar considerably re-
duces the non-specific binding of QDs to the cellular 
membrane. Hence, fluorescent nanocrystals, which 
usually adhere nonspecifically to human ovarian ad-
enocarcinoma SKOV-3 cells and penetrate them (Fig. 
3A), become virtually neutral with respect to these cells 
after conjugation with barstar (Fig. 3B). At the same 
time, the barstar located on the QD surface provides 34 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
REVIEWS
the additional binding of targeting antibodies using the 
barnase–barstar adaptor system, ensuring the efficient 
and specific labeling of cancer cells (Fig. 3C). 
An important advantage of the barnase–barstar 
module is the accurate (1 : 1) ratio between the compo-
nents in the complex and the total absence of self-ag-
gregation, as well as a high interaction affinity,   higher 
than that of all other dimerization systems, with the 
exception of the streptavidin–biotin system. As op-
posed to the streptavidin–biotin system, the use of the 
barnase–barstar system is based on genetic engineer-
ing technologies and requires no covalent modifications 
of antibodies.
The barnase–barstar adaptor system has been suc-
cessfully used for the preparation of fluorescent com-
plexes for the imaging of tumor cells overexpressing 
oncomarker HER2/neu, based on 4D5scFv antibod-
ies and QDs of two types 1) QDs modified by mercap-
toacetic acid and 2) QDs covered with a polymeric shell 
[45, 46]. In both of these cases, efficient and selective 
staining of membranes after the incubation of breast 
adenocarcinoma cells and human ovarian adenocarci-
noma cells with the obtained fluorescent complex was 
observed.
Furthermore, it was shown that QDs conjugated to 
targeting antibodies, with the help of adaptors, can be 
bound to molecules or nanoparticles of a different na-
ture. Thus, they can be regarded as components of a 
“Molecular Lego kit” [43]. By implementing the con-
ception of such a Lego kit, self-assembling multimodal 
structures were designed on the basis of the barnase–
barstar adaptor module using QDs and magnetic parti-
cles. The resulting fluorescent magnetic nanoparticles 
are supplied with humanized mini-antibodies against 
the HER2/neu oncomarker and can efficiently and se-
lectively label the corresponding tumor cells [28]. As a 
result, fluorescence-labeled tumor cells acquire respon-
siveness to a magnetic field (Fig. 4).
2.3 The problem of nonspecific binding of QDs
QD tendency to “adhesion,” i.e., nonspecific binding 
to the cellular membrane, proteins, and components 
of the extracellular matrix, and their uncontrolled 
penetration into cells is a significant impediment to 
selective QD-based fluorescence labeling of biological 
objects. For example, particles with a strong negative 
or positive charge containing on their surface car -
boxyl or amino groups, respectively, were shown to 
possess a high level of nonspecific binding with cells 
and tissues [47, 48]. Such nonspecific binding can be 
explained by the electrostatic interaction between 
charged groups on the QD surface and the charged 
regions of proteins and other molecules on the cel -
lular surface. 
 An additional explanation for the nonspecific bind-
ing of QDs with the cellular surface may be the hydro-
phobic interaction between the lipids in the cellular 
membrane and the stabilizing agent molecules (e.g., tri-
n-octylphosphine or oleate anion) that remain on the 
QD surface after their synthesis due to the incomplete 
coating of a nanoparticle core with a ligand providing 
hydrophility, or due to instable binding of this ligand. 
Thus, it was shown that QDs comprising cysteine, 
MAA, dihydrolipoic, and other mercapto-carboxylic ac-
ids, notable for their dynamic and instable Zn–S bond, 
exhibit the highest level of nonspecific binding [47].
It was determined that the degree of nonspecific 
binding strongly depends on the cell type [47, 49], which 
can be explained by different contents of charged and 
hydrophobic regions on the membrane of particular 
cells.
In order to reduce the degree of nonspecific bind-
ing, QDs are additionally coated with a layer of inert 
molecules. One such substances, widely used now, 
is PEG, a nontoxic hydrophilic polymer commonly 
used for enhancing the biocompatibility of drugs [48]. 
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Fig. 3. Non-specific and specific interaction of QDs with 
tumor cells. Schematics (on the left) and results (on the 
right) of fluorescent microscopy of SKOV-3 cells after 
incubation with QD (А), with QD-barstar (B), and with 
anti-HER-2/neu scFv dimer joined with barnase, following 
QD-barstar (C). Cell images in visible light (a, b, c) and 
fluorescent cell images (a’, b’, c’) are shown. Legend see 
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Quantum dots modified by PEG have a surface charge 
that is close to neutral and remain colloidally stable 
under various experimental conditions. Furthermore, 
PEG reduces the ability of QDs to interact with the 
cell surface or with the proteins of an extracellular 
matrix; i.e., it results in the passivation of the QD sur-
face [50].
In the case of PEG-coated QDs, it should be noted 
that despite the fact that they are successfully used 
both in vitro and in vivo experiments, such a modifica-
tion is not sufficient for some other purposes. Further-
more, PEG-coated particles have a considerably higher 
hydrodynamic diameter, which impedes their access to 
biological targets [51].
In order to minimize the nonspecific binding of QDs 
without increasing their size, a method for coating na-
nocrystals with a neutral hydroxyl layer was proposed 
[52]. The hydrodynamic diameter of the resulting na-
nocrystals is 13–14 nm, which is smaller than the size 
of PEG-modified nanocrystals by 50%. When using the 
obtained complexes for HeLa cells imaging, 140-fold 
and 20-fold reductions of nonspecific binding, in com-
parison with carboxylated QDs and biotin-conjugated 
QDs, respectively, were observed. To perform the tar-
geted delivery of such nanocrystals, it is necessary to 
supply them with targeting molecules, resulting in a 
partial loss of material and a decrease in the yield of the 
final product. Meanwhile, it is quite realistic to reduce 
the nonspecific adhesion of QDs on the cellular mem-
brane and simultaneously provide nonspecific binding 
of a nanoparticle to certain receptors expressed on the 
surface of a tumor cell. It was noted that some small 
neutral molecules, such as peptides or small proteins, 
enable to reduce the nonspecific binding of QDs [52]. 
We demonstrated that the component of the adaptor 
system, barstar, also possesses this property (see above 
Section 2.2, Fig. 3).
3. In vitro DIAGNOSTICS 
One of the most promising and rapidly developing ar-
eas of application of QDs is their usage as fluorescent 
labels during in vitro study of tumor cells: for imag-
ing tumor cells and for localizing the individual mole-
cules expressed in them. The unique properties of QDs, 
which make it possible to perform multicolor labeling 
and long-term observation of fluorescence of objects, 
allow one to considerably broaden the range of con-
ventional methods that are used in this field. In vitro 
diagnostics is now the only application of QDs out of all 
alternatives of the biomedical use of QDs which can be 
quickly implemented in clinical practice (as opposed to 
the in vivo use of QDs, which requires long investiga-
tions of QD toxicity and further consequences of their 
introduction into the organism).
The major directions of investigation include: 1) imag-
ing of tumor cells overexpressing certain oncomarkers, 
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“MF” foil under cover slip
Foil is magnetized Barnase Barstar 4D5scFv-barnase-4D5scFv
Fig. 4. Superstructures consisting of QDs, magnetic particles (MP), and scFv antibodies. Conceptual design of super-
structures based on barnase-barstar adaptor system (on the left), and multifunctionality proving (on the right). Human 
ovarian cancer SKOV-3 cells labeled by the assembled trifunctional structures were dragged toward the contour of 
letters “MF” (A). Bright-field (B - 100x magnification and D - individual cells) and fluorescent (C - 100x magnification and 
E - individual cells) photos of the sample. Adapted by permission from the National Academy of Sciences of the United 
States of America: [Proc. Natl. Acad. Sci. USA] (Nikitin M.P., Zdobnova T.A., Lukash S.V., Stremovskiy O.A., Deyev 
S.M. Proc Natl Acad Sci USA. 2010 107:5827-5832), copyright (2010).36 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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2) staining of tissues and their sections; and 3) observa-
tion of individual molecules and cells in real time. 
3.1 Imaging of tumor cells
The imaging of tumor cells and identification of the in-
dividual oncomarkers within them is of great practical 
importance. Most of the oncomarkers used for imag-
ing are represented by receptors overexpressed on the 
membrane surface of tumor cells, and they are almost 
non-expressed in normal tissues. A high level of expres-
sion of such markers correlates with a tumor process in 
the organism; their detection and quantitative assess-
ment being important for the early diagnostics, clas-
sification, and therapy of tumors [51]. 
 Several years after pioneering studies on the design 
and use of biocompatible QDs were published [14, 15], 
a few research groups claimed that it was possible to 
use QD conjugates for the imaging of tumor cells. Thus 
far, QDs conjugated to various targeting agents (anti-
bodies, ligands, peptides) have been known. They are 
intended for visualizing the cells of clinically significant 
human tumors: prostate carcinoma [53], breast adeno-
carcinoma and ductal carcinoma [21, 54, 55], pancreatic 
carcinoma [56], glioblastoma [32], and squamous cell 
carcinoma of the tongue [57].
Efforts in this area have primarily focused on the 
optimization of the properties of QDs for their appli-
cation in experiments in vivo and at the whole-body 
level. The preliminary purpose was a good solubility 
in aqueous solutions, biocompatibility, low toxicity of 
QDs, and additionally their supplying with targeting 
molecules providing the specificity of labeling. Over a 
short period of time, appreciably simple, inexpensive, 
and well reproducible QD-based methods for the im-
aging of cancer cells were designed for the diagnostics 
of clinically significant tumor types and prognosis of 
the disease’s progresson (Table). Hence, significant me-
thodical groundwork was laid for implementing these 
methods in clinical practice and further in vivo studies 
aimed at the imaging of tumors and their metastases 
directly in the living organism.
3.2 Simultaneous detection of several oncomarkers 
Generally, targeting molecules (antigens, peptides, 
aptamers, etc.) that selectively bind to the surface on-
comarker provide a high specificity of labeling of the 
corresponding tumor cells [17]. At the same time, such 
a feature of tumor cells as their extreme variability 
during the development of the disease and response to 
the action of therapeutic agents raises for researchers 
the problem of simultaneous imaging of several surface 
markers (see Section 1).
The fundamental possibility of using QDs for simul-
taneous multiplex detection was demonstrated on five 
tumor markers in a human breast tumor cell culture. 
The simultaneous detection of the receptors ER, PR, 
EGFR, mTOP, and HER2/neu using QDs fluorescing in 
different spectrum regions correlates positively with 
the results of conventional methods; including immu-
nohistochemistry, western blotting, and fluorescence in 
situ hybridization, while it considerably increases the 
rate of analysis and reduces cost [61]. 
Simultaneous imaging of two hypothesized cancer 
markers - integrin αvß3 and nucleolin-using QDs con-
jugated to the RGD peptide and aptamer AS1411, re-
spectively, enables to compare the localization of these 
markers in the cell [36]. Internalization of nucleolin and 
the surface distribution of integrin were confirmed us-
ing confocal microscopy, which will probably allow to 
better understand how they participate in the proc-
esses occurring in tumor cells.
The results of these studies demonstrate that QDs 
conjugated to targeting molecules have a powerful po-
tential as components of novel systems for assessing tu-
mor types, their progression stage, and the metastatic 
potential on the basis of multiplex imaging. 
Fundamental studies of oncological processes, in ad-
dition to the detection of the markers that are overex-
pressed in cancer cells, require that a number of oth-
er proteins, frequently characterized by a low-copy 
number, be revealed. The golden standard today for 
identifying low-copy number proteins is enzyme-linked 
immunosorbent assay (ELISA); its sensitivity attains 
the picomolar value. This method has been widely used; 
however, it is quite labor-intensive, expensive, time-
consuming, and does not allow for multiplexing. The re-
placement of organic fluorophores and colorimetric rea-
gents in immune enzyme studies by QDs alone does not 
provide a significant advantage in terms of sensitivity 
(the sensitivity of the analysis with QDs is ~ 100 pmol) 
[70]. It is the application of QDs with different spectral 
characteristics which allows simultaneous detection 
of several proteins to be performed. Thus, four toxins 
were simultaneously detected using four different QDs, 
which emitted between 510 and 610 nm, in a sandwich 
immunoassay configuration with a single extitation 
source [70]. Unfortunately, these authors have not man-
aged to carry out the quantitative assessment at this 
stage; further investigations are required to design a 
good immunofluorescence test. Another study demon-
strated the simplicity and obviousness of the simultane-
ous detection of two proteins with two spectrally dif-
ferent QDs in a western blot assay [71]. Unquestionably, 
simultaneous multicolor labeling using QDs is a novel 
and powerful method that will allow us to solve both 
conventional and fundamentally new problems that 
previously could not be solved or were extremely labor-
intensive when  conventional approaches were used.REVIEWS
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Simultaneous multiplex labeling using QDs with 
different spectral characteristics also provides indis-
putable advantages in studies requiring high-per-
formance screening of molecules. QDs are success-
fully used for the analysis of various components of 
cell systems using microarray technology and for the 
parallel analysis of the genome and proteome content 
of healthy and affected cells [72]. The brightness and 
stability of QDs significantly increase the sensitivity 
and the possibility of parallel detection of the com -
ponents of complex mixtures. The results obtained 
can help better understand the signal paths in cells, 
as well as be used in the design of new therapeutic 
approaches.
3.3 Immunohistochemical assay
Immunohistochemical assay (IHC) is the method for 
tumor diagnostics most widely used in clinical practice.   
This method of morphological study is based on imag-
ing and microscopic evaluation of the results of the an-
tigen–antibody reaction in biopsied tissue sections and 
allows not only to detect the presence and intensity of a 
signal, but also to evaluate signal distribution over the 
cell (staining of the membrane, cytoplasm, nucleus, and 
other structural elements). Immunochemical staining 
of formaldehyde-fixed and paraffin-embedded tissue 
sections of tumor biopsy samples is a complicated task 
because of high tissue autofluorescence and the reduc-
tion of the amount of antigen during the fixation and 
paraffin embedding.
QDs appeared very well-suited for the resolution of 
this problem. Images of fixed sections of human skin ba-
sal carcinoma [60], mouse breast tumor overexpressing 
the human receptor HER2/neu [16], and basal-squa-
mous cell carcinoma of human skin [73] were obtained 
using QDs. It was also demonstrated by the example of 
the human breast tumor that QD-based probes can be 
designed for quantitative and highly sensitive detection 
of the low expression of cancer surface markers, in par-
ticular, oncomarker HER2/neu [74]. Researchers have 
also noted the excellent photostability of QD-stained 
samples: their fluorescence intensity remains intact for 
9–75 days [74] (Fig. 5).
The combination of conventional IHC procedures 
with QD-based fluorescent dyes allows one to consid-
erably improve the resolution and sensitivity of the 
method (see review [17]) and provides a possibility of si-
multaneous imaging of several markers [75]. Moreover, 
the application of QDs makes the IHC method much 
more illustrative (Fig. 5).
3.4 Real-time  detection of molecular processes and 
cells 
The high resistance of QDs to photobleaching and their 
high level of brightness enable us to use them for imag-
ing of the processes occurring in cells, including trac-
А
C D
B Fig. 5. Advantages of QDs for 
immunohistochemical assays. 
A – Specimens with different 
HER2 IHC scores detected by 
QD-IHC (A) and by conven-
tional IHC using peroxidase 
(B). Preservation of QD fluo-
rescence and photobleaching 
on day 2 (C) and day 75 (D). 
Scale bar 100 µm. Adapted 
by permission from Elsevier: 
[Biomaterials] (Chen C, Peng 
J, Xia H, Yang G, Wu Q, Chen 
L, Zeng L, Zhang Z, Pang D, Li 
Y. Biomaterials. 2009 30:2912-
2918), copyright (2009).38 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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ing the dynamics of individual molecules [41]. Certain 
membrane proteins are of special interest; the inves-
tigation of their localization and dynamics is crucial in 
understanding such processes as chemotaxis and inter- 
and intracellular signal transduction. Thus, QDs conju-
gated with the corresponding targeting ligands have 
been successfully used for imaging of the dynamics of 
the receptors of glycine [12] and γ-amino butyric acid 
[76] in a neuron cell culture.
Since a vast number of significant oncomarkers are 
represented by proteins which have regulatory func-
tions in normal cells and which participate in signal 
transduction, study of the functioning of these proteins 
is important for understanding the nature and mech-
anisms of the malignization process. QDs conjugated 
with an epidermal growth factor (EGF) were used to 
study the mechanisms of EGF internalization and sig-
nal transduction pathways with the participation of 
proteins from the erbB1/2/3 family of transmembrane 
tyrokinase receptors [11].
It was demonstrated that QDs can be used to study 
the motility of tumor cells with the purpose of determin-
ing their invasive potential [77]. Use of QDs as markers 
for imaging of the trajectory of cell motion is less labori-
ous and allows to obtain more reliable data as compared 
with the conventional Boyden’s chamber assay.
These novel and extremely interesting directions of 
study have as yet not found application in clinical diag-
nostics; however, they will undoubtedly be developed 
as a domain of fundamental science and will help to ob-
tain new knowledge on tumor pathogenesis.
4. In vivo ANIMAL IMAGING 
During the past five years, considerable progress has 
been made in the application of QDs as fluorophores in 
experiments on cells and fixed tissues. Meanwhile, the 
use of these nanoparticles for imaging in multicellular 
organisms, especially in such highly organized ones as 
mammals, is only in the early stages of development.
Two major problems emerge during fluorescent la-
beling at the whole-body level: 1) signal attenuation 
due to the increased size of the organism and tissue 
thickness, and 2) the difficulty of delivering fluoro-
phores to the target cells and tissues.
A significant obstacle is the depth of fluorescence 
penetration, since biological tissues absorb most of the 
signals that are used for imaging; furthermore, they 
are characterized by a considerable autofluorescence 
in the green region of the spectrum. However, in the 
IR region there exists the so-called “optical window” 
(650–1300 nm), in which light absorption by living tis-
sues is minimal. The existence of such a window results 
from the fact that the minimum level of absorption of 
the major chromophores in mammals (blood, flavins, 
vitamins, and NAD(P)H) lies in this region [78]. That is 
why for in vivo imaging, QDs fluorescing in the near-
Normal  
vascular wall Tumor  
vascular wall
Active targeting
Passive targeting
Targeted QD
Non-targeted QD
Endothelial cell
Tumor cell with specific  
surface receptors
Fig.6. Schematic il-
lustration of passive 
and active tumor-
targeting after sys-
tem administration 
of QD.REVIEWS
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IR region (700–800 nm) are used, allowing to improve 
the brightness of the resulting signal and to reduce the 
background.
Fluorophore delivery to target cells in the organism 
of a mammal is complicated and consists of multiple 
stages, since the substances being delivered need to 
penetrate  through a number of structural and physi-
ological barriers, including the vascular endothelium, 
the immune barrier, and the metabolic degradation of 
the introduced substances. Moreover, after system ad-
ministration the fluorophore can be delivered via the 
blood stream into non-target organs and organism tis-
sues and  accumulate there, thus reducing the contrast 
and increasing the possibility of false-positive signals 
and the manifestation of a toxic effect. Therefore, the 
excess fluorophore that has not bound to the target 
cells should be quickly and completely removed from 
the organism.
4.1 Tumor detection using QDs
In a living organism, accumulation of QDs injected in-
travenously in tumor tissue for its subsequent imag-
ing is possible through two mechanisms: 1) a passive 
mechanism, which is typical of particles of a certain 
size, and 2) an active mechanism, using the targeting 
agent [53] (Fig. 6).
In the case of the passive mechanism, nanometer-
sized particles accumulate preferentially at tumor 
site due to its structural features. Such particles can 
penetrate into a tumor with ease, due to the increased 
permeability of vascular walls, and remain there as a 
result of the impaired lymphatic drainage therein. It 
has been demonstrated that the capillary permeability 
of the endothelial barrier in newly vascularized tumors 
is considerably higher than that in normal tissues. Nor-
mal blood vessels are lined with a unfenestrated en-
dothelium; hence, the penetration of macromolecules 
and nanoparticles into the tissue is impeded. Blood ves-
sels formed during the tumor-induced angiogenesis are 
characterized by a nontypical structure and wide en-
dothelial pores. These pores are so large that molecules 
up to 400 nm in size can leave the vessels and accumu-
late in tumor tissue [79]. Moreover, there is almost no 
lymphatic drainage in tumor tissue; therefore, macro-
molecules stay there for a considerable amount of time. 
The described enhanced permeability and retention 
effect (EPR) is used for the delivery of therapeutic and 
diagnostic agents based on latexes, liposomes, and oth-
er particles into tumors [80].  In the case of the passive 
delivery, nontargeted PEG-coated QDs that possess a 
minimal level of nonspecific binding with proteins and 
blood cells are used [53].
To provide active delivery of QDs to tumors, they 
are supplied with targeting molecules capable of bind-
ing to the specific receptors exposed on the tumor cell 
surface (see Section 2.1).
The possibility of intravital labeling of tumors with 
quantum dots was first demonstrated on mouse models. 
It was demonstrated that after intravenous adminis-
tration, QDs conjugated to peptides specific to various 
types of tumors and their vessels are selectively accu-
mulated in the tumor vasculature [31].
The first progress in the in vivo application of QDs 
has stimulated a large number of studies devoted to the 
intravital imaging of human model tumors in animal 
organisms using QDs targeted at different tumor mark-
ers. Full-size antibodies and their fragments, specific 
peptides, and natural ligands were used as targeting 
ligands with equal success (Table). The results of these 
studies demonstrate that the use of the mechanism of 
active targeting, as compared with that of passive tar-
geting, considerably enhances QD accumulation in the 
tumor regardless of the type of QDs employed and of 
the type of the targeting agent (Fig. 7). The use of tar-
geted QDs as fluorophores, in combination with modern 
optical imaging methods, allows to perform imaging of 
not only solid tumors, but also metastases in organs [65] 
and bone tissue [58] and to reveal micrometastases at 
the early stages of the disease [81]. It should be noted 
that in all cases, along with successful labeling of tu-
mors in vivo using both the active and passive mecha-
nisms, nonspecific accumulation of QDs in different or-
gans of model animals was observed, primarily, in the 
liver, spleen, and lymph nodes (Fig. 7).
In addition, locally introduced QDs can also be of 
great diagnostic significance. Thus, it was demon-
strated that QDs of different colors injected into the 
peripheral areas of the body were located in different 
lymph nodes, giving different coloration to them [82]. 
In recent times, a significant number of studies have 
been devoted to the imaging of sentinel lymph nodes, 
along which the metastatic spread typically occurs [83, 
84]. Intraoperative imaging of the primary tumor, along 
with sentinel lymph nodes, provides the possibility of 
determining the size of the surgery field and the neces-
sity of lymphodissection [85].
The size of QDs and their ability to induce two-pho-
ton excitation have prompted researchers to investi-
gate the potential of these particles as promising con-
trast agents for angiography; possible alternatives to 
the fluorescent dextrane conventionally used for these 
purposes. Because of the large cross-section of two-
photon absorption (larger than that of conventional or-
ganic dyes by 2–3 orders of magnitude), QDs can be ex-
cited in the IR range. This fact allows to attain a higher 
resolution at a great tissue depth (since long waves are 
less scattered than short waves) and reduce the level of 
phototoxicity (the exciting photons in the IR region of 40 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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the spectrum possess a lower energy; therefore, they 
are less destructive for the tissue under investigation) 
[86]. Indeed, the use of two-photon excitation of QDs 
for contrasting the blood vessels of tumor cells consid-
erably enhances the imaging contrast, in comparison 
with conventional methods [87].
Thus, the results of intravital imaging of tumors pre-
sented above demonstrate that, due to the high level of 
absorption by organs of the reticuloendothelial system 
(RES) and the absence of complete removal from the 
organism (see Section 5.2 of this review), the clinical 
application of QDs as contrast agents for in vivo imag-
ing is accompanied by certain difficulties. At the same 
time, the exceptional brightness, high quantum yield, 
and large cross section of two-photon absorption, which 
determines the fluorophore brightness in multiphoton 
microscopy, allow to successfully utilize QDs as imaging 
agents for the study of the anatomy and pathophysiol-
ogy of tumors on animal models. The use of QDs con-
siderably improves the existing methods of intravital 
microscopy of tumors and their microenvironment. The 
combination of the exceptional spectral properties of 
QDs and modern technologies that allow us to obtain in 
vivo images with high resolution may result in a con-
siderable breakthrough in the understanding of tumor 
biology.
4.2 QD biodistribution and pharmacokinetics 
The key success factor of in vivo diagnostics of tumors 
are: high fluorophore content in a tumor, in comparison 
with that found in normal tissues and blood, and the 
absence of false-positive signals. In addition, it is essen-
tial that diagnostic agents be capable of rapid excretion 
from the organism. 
It was demonstrated in vitro that the action and bio-
logical fate of QDs in the cell depends to a considerable 
extent on the size and chemical properties of the sur-
face of these particles [88, 89]. The same parameters 
were assumed to play a significant role in the distribu-
tion of QDs in the organism, as well.
 When studying the biodistribution of QDs in the 
organism of model animals, it turned out that all QDs 
were completely cleared from the bloodstream to accu-
mulate in organs and tissues [90], mostly in RES organs 
(liver, spleen and lymph nodes). Similar results were 
obtained in tumor imaging: along with label accumula-
tion in tumor, some QDs also remained in RES organs 
[25, 31, 32, 53, 65]. Almost in all cases, no QDs were de-
tected in the lung, heart, muscle, or brain tissues; in a 
number of studies, a small amount of QDs was found in 
the kidneys. Contrary to expectations, such distribution 
was independent of surface properties and the type of 
targeting agent (or the absence of it) conjugated with 
QD, while the presence of PEG on the particle surface 
resulted in a slight increase in its blood half-life but did 
not completely prevent accumulation in these organs. 
The QD blood half-life varied from several minutes to 
several tens of hours and depended to a large extent on 
their hydrodynamic diameter [91], as well as the sur-
face charge and structure [92].
In this context, direct comparison of QDs and the 
standard organic dye Alexa Fluor 680, both conjugat-
ed with anti-IGF1R-antibodies in experiments in vivo 
on model animals, is of interest [55]. It was shown that 
both fluorophores can allow specific imaging of breast 
tumor; however, QDs are considerably poorer excreted 
from the organism, accumulating in RES organs.
The initial results of the investigation of the effect 
of the size and dimensions of the QD surface on their 
distribution in the organism after intravenous admin-
istration are quite controversial. It was shown in a se-
ries of studies that the surface coating [93, 93] and size 
Fig. 7. In vivo fluorescence imaging of U87MG tumor-
bearing mice (left shoulder, indicated by white arrows) 
injected with targeted (left) and nontargeted QD (right). 
The mice autofluorescence is color-coded green, while 
the unmixed QD signal is color-coded red. Prominent 
uptake in the liver, bone marrow, and lymph nodes was 
also visible. Reprinted by permission from the American 
Chemical Society: [Nano Letters] (Cai W, Shin D.W., 
Chen K, Gheysens O, Cao Q, Wang S.X., Gambhir S.S., 
Chen X. Nano Lett. 2006 6:669–676), copyright (2006).REVIEWS
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[94] have a significant effect on the pharmacokinetics 
and biodistribution of the particles. Conversely, in the 
systematic study [95] performed in view of all factors 
that may have an effect on biodistribution, no signifi-
cant differences were observed for QDs of different 
sizes, different charges, and those with the presence 
or absence of different molecules (albumin, PEG) on 
the surface – all QDs mostly accumulated in the liver 
and spleen.
QDs can be excreted from the organism via two 
paths: via the kidneys and the liver [93, 96]. The ex-
cretion path to the largest extent depends on two pa-
rameters of the particle: their size and surface coating, 
which determines the tendency towards adsorption 
of the proteins of the blood serum [78]. The investiga-
tion of the excretion from the organism of specially de-
signed series of QDs of different sizes and with differ-
ent coatings [59] demonstrated that one of the required 
condition for the full excretion of nanoparticles from 
the organism via the kidneys is a value of the hydrody-
namic diameter of a QD less than 5.5 nm (i.e., below the 
renal filtration threshold). Currently, all synthesized 
QDs with fluorescence in red and near-IR ranges that 
are used for in vivo imaging possess a higher size value 
(approximately 10 nm) and cannot be removed from 
the organism via the kidneys. Moreover, these QDs are 
coated with a polymer to improve stability and contain 
charged functional groups and PEG on their surface, 
which further increases their size. Thus, the hydrody-
namic diameter of popular commercial QDs (Invitro-
gen) is 15–19 nm [82]. There is only a single excretion 
path for such non-biodegradable QDs: via the liver, 
with bile. This process is very slow and inefficient; and 
the long-term stay of nanoparticles in RES organs in-
creases the possibility of QD shell degradation and the 
rise of a toxic effect. Thus, although QDs are ideally 
suitable for in vivo imaging of tumors in terms of their 
parameters, with the exception of their hydrodynamic 
diameter, their accumulation in the liver, spleen, and 
other RES organs is inevitable. Interestingly, a number 
of authors mention the renal accumulation of QDs with 
a hydrodynamic diameter significantly higher than the 
renal filtration threshold [95, 97]. In the absence of ad-
ditional studies, it is difficult to say whether these data 
are an artifact or attest to some other unstudied mech-
anisms of interaction between nanoparticles and the 
living organism. Either way, the complicated excretion 
from the organism remains one of the major impedi-
ments to the use of QDs in the human organism.
5. RISKS IN USING QDS IN BIOLOGICAL 
AND MEDICAL STUDIES
The unique physicochemical properties of QDs make 
them extremely attractive fluorophores for the in vivo 
imaging of living objects. The pioneering studies in this 
field began quite recently (less than 10 years ago); in 
fact the search for a design of QD optimal for these 
purposes is ongoing.  In this regard, QDs that are used 
by different laboratories strongly differ in such param-
eters as their size, shape, charge, concentration, oxida-
tion-reduction properties, surface coating, and physical 
stability. A wide range of these parameters, in combi-
nation with various experimental conditions (treatment 
time, selection of the model cell lines and media, using 
the same concentration units, the presence or absence 
of a targeting agent) make it considerably more dif-
ficult to compare the published data on QD biosafety 
and to get a broad outline.  Despite this fact, in a field 
of extremely diverse and controversial information, a 
number of regularities have been revealed [90, 98].
5.1 QD citotoxicity
The cytotoxic effect of QDs is largely determined by 
four main factors: the presence of heavy metal ions in 
their composition, the ability to generate reactive oxy-
gen species (ROS), colloidal instability, and nonspecific 
interaction with biological molecules [90, 98].
First-generation QDs, consisting only of the fluores-
cent core (CdTe or CdSe) and stabilized by thiol ligands 
(e.g., cysteine or MAA), can easily be subjected to oxi-
dation and degradation to release toxic cadmium ions 
[99] and are capable of inducing ROS formation [100]. 
Such particles are extremely toxic for culture cells even 
in small concentration; hence, they are not suitable for 
investigations on living objects. Second-generation QDs 
are coated with a shell made of an inert zinc sulfide 
in order to prevent non-radiative energy dissipation. 
Moreover, it was found that such a shell actually im-
pedes oxidation and degradation of the fluorescent core 
and hinders the release of cadmium ions, considerably 
reducing cytotoxicity. Meanwhile, insufficient colloidal 
stability is typical of QDs stabilized by an inexpensive 
and simple method using small thiol ligands [99]. The 
deposition of such QD aggregates on the cell surface, 
even without penetration of the cell, may lead to physi-
cal damage, functional abnormalities, and as a result, 
cell death [89]. In principle, second-generation QDs can 
be used for short-term investigations on cell cultures; 
however, a significant risk exists when they are used 
in organisms.
Today, third-generation QDs are used in most bio-
logical studies; they are represented by CdSe/ZnS par-
ticles coated by a polymeric or silicon shell. These QDs 
possess a much higher colloidal, chemical, and optical 
stability as compared with their analogues coated with 
small ligands. The third-generation QDs manifest some 
toxicity in cell cultures only under extreme conditions 
or when used at concentrations that exceed the con-42 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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)
J
5
9
1
Q
d
o
t
®
 
8
0
0
 
A
n
t
i
b
o
d
y
 
C
o
n
j
u
g
a
t
i
o
n
 
K
i
t
 
(
I
n
v
i
t
r
o
g
e
n
)
W
h
o
l
e
-
b
o
d
y
 
i
n
 
v
i
v
o
 
i
m
a
g
i
n
g
 
u
s
i
n
g
 
I
V
I
S
 
I
m
a
g
i
n
g
 
S
y
s
t
e
m
T
a
r
g
e
t
e
d
 
Q
D
 
w
e
r
e
 
u
s
e
d
 
s
u
c
-
c
e
s
s
f
u
l
l
y
 
f
o
r
 
b
o
n
e
 
m
e
t
a
s
t
a
s
e
s
 
d
e
t
e
c
t
i
o
n
.
 
[
5
8
]
*
L
N
C
a
P
G
P
I
 
p
e
p
t
i
d
e
C
y
s
t
e
i
n
e
-
c
o
a
t
e
d
 
C
d
S
e
/
Z
n
C
d
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
,
 
P
E
G
y
l
a
t
e
d
 
F
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
c
e
l
l
s
,
 
i
n
t
r
a
o
p
e
r
a
t
i
v
e
 
f
l
u
o
r
e
s
-
c
e
n
t
 
p
o
s
t
 
m
o
r
t
e
m
 
i
m
a
g
i
n
g
 
o
f
 
i
n
t
e
r
n
a
l
 
o
r
g
a
n
s
 
S
m
a
l
l
 
I
R
 
Q
D
s
 
f
o
r
 
i
n
 
v
i
v
o
 
i
m
a
g
i
n
g
 
w
e
r
e
 
c
r
e
a
t
e
d
.
 
[
5
9
]
*
α
v
β
3
 
i
n
t
e
g
r
i
n
R
G
D
 
p
e
p
t
i
d
e
B
r
e
a
s
t
 
c
a
n
c
e
r
M
D
A
-
M
B
-
4
3
5
 
(
d
u
c
t
a
l
 
c
a
r
c
i
-
n
o
m
a
)
E
n
d
o
t
h
e
l
i
u
m
 
o
f
 
t
u
m
o
r
 
b
l
o
o
d
 
v
e
s
s
e
l
s
G
F
E
 
a
n
d
 
L
y
P
-
1
 
p
e
p
t
i
d
e
s
M
A
A
-
c
o
a
t
e
d
 
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
C
o
n
f
o
c
a
l
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
c
e
l
l
s
 
a
n
d
 
t
i
s
s
u
e
 
s
e
c
t
i
o
n
s
A
u
t
h
o
r
s
 
p
o
s
t
u
l
a
t
e
d
 
t
h
a
t
 
Q
D
 
P
E
G
y
l
a
t
i
o
n
 
p
r
e
v
e
n
t
s
 
n
o
n
s
e
l
e
c
-
t
i
v
e
 
a
c
c
u
m
u
l
a
t
i
o
n
 
o
f
 
Q
D
 
i
n
 
R
E
S
.
[
3
1
]
*
 
S
K
B
R
-
3
 
(
a
d
e
n
o
-
c
a
r
c
i
n
o
m
a
)
 
H
E
R
2
/
n
e
u
T
r
a
s
t
u
z
u
m
a
b
/
H
e
r
c
e
p
t
i
n
®
 
(
h
u
m
a
n
i
z
e
d
 
m
o
n
o
c
l
o
n
a
l
 
f
u
l
l
-
s
i
z
e
 
a
n
t
i
b
o
d
y
)
 
C
a
r
b
o
x
y
l
 
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
s
t
a
b
i
l
i
z
e
d
 
w
i
t
h
 
a
m
p
h
i
p
h
i
l
i
c
 
p
o
l
y
m
e
r
 
(
Q
u
a
n
t
u
m
 
D
o
t
 
C
o
r
p
o
r
a
t
i
o
n
)
F
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
f
i
x
e
d
 
c
e
l
l
s
Q
D
s
 
w
e
r
e
 
u
s
e
d
 
t
o
 
l
a
b
e
l
 
d
i
f
f
e
r
e
n
t
 
t
y
p
e
s
 
o
f
 
t
a
r
g
e
t
s
 
a
t
 
d
i
f
f
e
r
e
n
t
 
s
u
b
c
e
l
l
u
l
a
r
 
l
o
c
a
t
i
o
n
s
 
a
n
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
t
 
t
y
p
e
s
 
o
f
 
s
p
e
c
i
m
e
n
s
 
(
c
u
l
t
u
r
e
d
 
l
i
v
e
 
c
e
l
l
s
,
 
f
i
x
e
d
 
c
e
l
l
s
,
 
a
n
d
 
t
i
s
s
u
e
 
s
e
c
t
i
o
n
s
)
.
[
1
6
]
M
C
F
-
7
p
-
g
l
y
c
o
p
r
o
-
t
e
i
n
A
n
t
i
-
р
-
g
l
y
c
o
p
r
o
t
e
i
n
 
p
r
i
m
a
r
y
 
a
n
t
i
b
o
d
y
 
a
n
d
 
Q
D
-
c
o
n
j
u
g
a
t
e
d
 
a
n
t
i
-
m
o
u
s
e
 
p
o
l
y
v
a
l
e
n
t
 
g
o
a
t
 
s
e
c
o
n
d
a
r
y
 
a
n
t
i
b
o
d
y
C
y
s
t
e
i
n
e
-
m
o
d
i
f
i
e
d
 
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
c
o
a
t
e
d
 
w
i
t
h
 
p
o
l
y
m
e
r
 
b
e
a
r
i
n
g
 
s
u
r
f
a
c
e
 
a
m
i
n
o
 
g
r
o
u
p
 
C
o
n
f
o
c
a
l
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
c
e
l
l
s
,
 
f
l
u
o
r
e
s
c
e
n
t
 
I
H
C
 
H
i
g
h
e
r
 
p
h
o
t
o
s
t
a
b
i
l
i
t
y
 
o
f
 
Q
D
 
a
s
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
o
r
g
a
n
i
c
 
d
y
e
s
 
w
a
s
 
d
e
m
o
n
s
t
r
a
t
e
d
.
[
6
0
]
M
D
A
-
M
B
-
4
3
5
α
v
β
3
 
i
n
t
e
g
r
i
n
R
G
D
 
p
e
p
t
i
d
e
 
Q
d
o
t
®
 
7
0
5
 
I
T
K
™
 
a
m
i
n
o
 
(
P
E
G
)
 
q
u
a
n
t
u
m
 
d
o
t
s
»
 
(
 
I
n
v
i
t
r
o
g
e
n
)
F
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
c
e
l
l
s
_
_
_
[
3
2
]
M
C
F
-
7
 
(
a
d
e
n
o
-
c
a
r
c
i
n
o
m
a
 
а
)
,
B
T
-
4
7
4
 
(
d
u
c
t
a
l
 
c
a
r
c
i
n
o
m
a
)
E
G
F
R
,
 
H
E
R
2
/
n
e
u
F
u
l
l
-
s
i
z
e
 
m
o
n
o
c
l
o
n
a
l
 
a
n
t
i
b
o
d
y
Q
d
o
t
®
 
A
n
t
i
b
o
d
y
 
C
o
n
j
u
g
a
t
i
o
n
 
K
i
t
 
(
I
n
v
i
t
r
o
g
e
n
)
F
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
t
i
s
s
u
e
 
s
e
c
t
i
o
n
I
H
C
 
d
e
t
e
c
t
i
n
g
 
o
f
 
f
i
v
e
 
t
u
m
o
r
 
m
a
r
k
e
r
s
 
l
a
b
e
l
e
d
 
w
i
t
h
 
Q
D
.
[
6
1
]
K
P
L
-
4
 
H
E
R
2
/
n
e
u
T
r
a
s
t
u
z
u
m
a
b
/
H
e
r
c
e
p
t
i
n
®
Q
d
o
t
®
 
A
n
t
i
b
o
d
y
 
C
o
n
j
u
g
a
t
i
o
n
 
K
i
t
s
 
(
I
n
v
i
t
r
o
g
e
n
)
I
n
 
v
i
v
o
 
f
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
-
c
o
p
y
I
n
 
v
i
v
o
 
r
e
a
l
-
t
i
m
e
 
t
r
a
c
k
i
n
g
 
o
f
 
s
i
n
g
l
e
 
Q
D
 
a
f
t
e
r
 
i
.
v
.
 
i
n
j
e
c
t
i
o
n
.
 
[
5
4
]
*
S
K
-
B
R
-
3
,
 
M
C
F
-
7
/
H
E
R
2
H
E
R
2
s
c
F
v
 
a
n
t
i
b
o
d
y
 
f
r
a
g
m
e
n
t
C
a
r
b
o
x
y
l
 
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
p
o
l
y
m
e
r
-
c
o
a
t
e
d
 
Q
D
 
(
I
n
v
i
t
r
o
g
e
n
)
F
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
c
o
p
y
 
a
n
d
 
 
f
l
o
w
 
c
y
t
o
m
e
t
r
y
 
o
f
 
c
e
l
l
s
,
 
i
n
 
v
i
v
o
 
w
h
o
l
e
-
b
o
d
y
 
i
m
a
g
i
n
g
 
u
s
i
n
g
 
m
a
c
r
o
-
i
l
l
u
m
i
n
a
t
i
o
n
 
s
y
s
t
e
m
C
r
e
a
t
i
o
n
 
o
f
 
m
u
l
t
i
f
u
n
c
t
i
o
n
a
l
 
s
t
r
u
c
t
u
r
e
s
 
b
a
s
e
d
 
o
n
 
i
m
m
u
n
o
l
i
p
o
-
s
o
m
e
 
a
n
d
 
Q
D
.
[
6
2
]
K
P
L
-
4
H
E
R
2
/
n
e
u
T
r
a
s
t
u
z
u
m
a
b
/
H
e
r
c
e
p
t
i
n
®
Q
d
o
t
®
 
8
0
0
 
A
n
t
i
b
o
d
y
 
C
o
n
j
u
g
a
t
i
o
n
K
i
t
 
(
I
n
v
i
t
r
o
g
e
n
)
I
n
 
v
i
v
o
 
f
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
-
c
o
p
y
 
I
n
 
v
i
v
o
 
r
e
a
l
-
t
i
m
e
 
t
r
a
c
k
i
n
g
 
o
f
 
s
i
n
g
l
e
 
Q
D
 
a
f
t
e
r
 
i
.
v
.
 
i
n
j
e
c
t
i
o
n
.
[
6
3
]
*
M
C
F
-
7
I
G
F
1
R
A
V
E
-
1
6
4
2
 
(
h
u
m
a
n
i
z
e
d
 
m
o
n
o
c
l
o
n
a
l
 
a
n
t
i
b
o
d
y
)
Q
d
o
t
®
 
A
n
t
i
b
o
d
y
 
C
o
n
j
u
g
a
t
i
o
n
 
K
i
t
s
 
(
I
n
v
i
t
r
o
g
e
n
)
F
l
u
o
r
e
s
c
e
n
t
 
m
i
c
r
o
s
c
o
p
y
,
 
f
l
o
w
 
c
y
t
o
m
e
t
r
y
 
D
e
t
e
c
t
i
o
n
 
o
f
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
 
o
f
 
c
e
l
l
 
s
u
r
f
a
c
e
 
r
e
c
e
p
t
o
r
.
[
5
5
]REVIEWS
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L
i
v
e
r
 
c
a
n
c
e
r
H
C
C
L
M
6
 
(
h
e
p
a
t
o
c
e
l
l
u
l
a
r
 
c
a
r
c
i
n
o
m
a
)
A
F
P
M
o
u
s
e
 
a
n
t
i
-
h
u
m
a
n
 
A
F
P
 
m
o
n
o
c
l
o
n
a
l
 
a
n
t
i
b
o
d
y
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
m
o
d
i
f
i
e
d
 
t
h
i
o
g
l
y
c
o
l
i
c
 
a
c
i
d
I
n
 
v
i
v
o
 
s
p
e
c
t
r
o
s
c
o
p
y
 
i
m
a
g
i
n
g
 
a
n
d
 
p
o
s
t
 
m
o
r
t
e
m
 
c
o
n
f
o
c
a
l
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
t
u
m
o
r
 
P
a
s
s
i
v
e
 
a
n
d
 
a
c
t
i
v
e
 
Q
D
 
t
u
m
o
r
 
t
a
r
g
e
t
i
n
g
 
w
e
r
e
 
c
o
m
p
a
r
e
d
.
 
[
6
4
]
*
M
o
u
s
e
 
a
n
t
i
-
h
u
m
a
n
 
A
F
P
 
m
o
n
o
c
l
o
n
a
l
 
a
n
t
i
b
o
d
y
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
m
o
d
i
f
i
e
d
 
t
h
i
o
g
l
y
c
o
l
i
c
 
a
c
i
d
W
h
o
l
e
-
b
o
d
y
 
i
n
 
v
i
v
o
 
i
m
a
g
-
i
n
g
,
 
s
e
r
u
m
 
b
i
o
c
h
e
m
i
c
a
l
 
e
x
a
m
i
n
a
t
i
o
n
,
 
c
o
n
f
o
c
a
l
 
m
i
c
r
o
-
s
c
o
p
y
 
o
f
 
t
i
s
s
u
e
 
s
e
c
t
i
o
n
s
,
 
t
i
s
s
u
e
 
d
i
s
t
r
i
b
u
t
i
o
n
 
o
f
 
C
d
 
a
n
d
 
S
e
 
u
s
i
n
g
`
I
C
P
-
M
S
 
q
u
a
n
t
i
t
a
t
i
v
e
 
a
s
s
e
s
s
m
e
n
t
 
I
n
 
v
i
v
o
 
v
i
s
u
a
l
i
z
a
t
i
o
n
 
o
f
 
t
u
m
o
r
 
a
n
d
 
m
e
t
a
s
t
a
s
e
s
.
 
C
y
t
o
t
o
x
i
c
i
t
y
 
i
n
 
v
i
t
r
o
,
 
t
h
e
 
a
c
u
t
e
 
t
o
x
i
c
i
t
y
 
i
n
 
v
i
v
o
,
 
t
h
e
 
h
e
m
o
d
y
n
a
m
i
c
s
 
a
n
d
 
q
u
a
n
t
i
t
a
t
i
v
e
 
t
i
s
s
u
e
 
d
i
s
t
r
i
b
u
t
i
o
n
 
w
e
r
e
 
e
s
t
i
m
a
t
e
d
.
[
7
4
]
*
P
a
n
c
r
e
a
t
i
c
 
c
a
n
c
e
r
M
I
A
 
P
a
C
a
-
2
 
(
c
a
r
c
i
n
o
m
a
)
C
l
a
u
d
i
n
-
4
,
P
S
C
A
F
u
l
l
-
s
i
z
e
 
m
o
n
o
c
l
o
n
a
l
 
a
n
t
i
b
o
d
y
I
n
P
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
m
o
d
i
-
f
i
e
d
 
 
m
e
r
c
a
p
t
o
s
u
c
c
i
n
i
c
 
a
c
i
d
W
h
o
l
e
-
b
o
d
y
 
i
m
a
g
i
n
g
 
u
s
i
n
g
 
M
a
e
s
t
r
o
 
m
a
c
r
o
-
i
l
l
u
m
i
n
a
t
i
o
n
 
s
y
s
t
e
m
,
 
c
o
n
f
o
c
a
l
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
t
i
s
s
u
e
 
s
e
c
t
i
o
n
s
I
m
a
g
i
n
g
 
b
y
 
n
o
n
-
c
a
d
m
i
u
m
-
b
a
s
e
d
 
n
o
n
t
o
x
i
c
 
Q
D
 
[
5
6
]
M
I
A
 
P
a
C
a
-
2
E
G
F
R
s
c
F
v
 
a
n
t
i
b
o
d
y
 
f
r
a
g
m
e
n
t
C
d
S
e
/
Z
n
S
 
c
o
r
e
-
s
h
e
l
l
 
Q
D
 
c
o
a
t
e
d
 
a
m
p
h
i
p
h
i
l
i
c
 
p
o
l
y
m
e
r
 
w
i
t
h
 
P
E
G
 
C
o
n
f
o
c
a
l
 
m
i
c
r
o
s
c
o
p
y
 
o
f
 
t
i
s
s
u
e
 
s
e
c
t
i
o
n
s
T
i
s
s
u
e
 
d
i
s
t
r
i
b
u
t
i
o
n
 
o
f
 
t
a
r
g
e
t
e
d
 
a
n
d
 
n
o
n
-
t
a
r
g
e
t
e
d
 
Q
D
 
w
a
s
 
i
n
v
e
s
-
t
i
g
a
t
e
d
[
2
5
]
*
C
o
l
o
r
e
c
t
a
l
 
c
a
n
c
e
r
H
C
T
1
6
6
E
G
F
R
E
G
F
Q
d
o
t
®
 
8
0
0
 
I
T
K
™
 
a
m
i
n
o
 
(
P
E
G
)
 
q
u
a
n
t
u
m
 
d
o
t
s
 
(
I
n
v
i
t
r
o
g
e
n
)
W
h
o
l
e
-
b
o
d
y
 
i
n
 
v
i
v
o
 
i
m
a
g
i
n
g
 
u
s
i
n
g
 
I
V
I
S
 
s
y
s
t
e
m
,
 
e
x
 
v
i
v
o
 
f
l
u
o
r
e
s
c
e
n
t
 
i
m
a
g
i
n
g
 
o
f
 
o
r
g
a
n
s
T
h
r
e
e
 
d
i
s
t
i
n
c
t
 
p
h
a
s
e
s
 
o
f
 
t
u
m
o
r
 
i
n
f
l
u
x
,
 
c
l
e
a
r
a
n
c
e
 
a
n
d
 
e
q
u
i
l
i
b
r
a
-
t
i
o
n
 
o
f
 
a
c
c
u
m
u
l
a
t
i
o
n
 
o
f
 
t
a
r
g
e
t
e
d
 
a
n
d
 
n
o
n
-
t
a
r
g
e
t
e
d
 
Q
D
 
w
e
r
e
 
o
b
s
e
r
v
e
d
[
6
6
]
 
*
C
e
r
v
i
c
a
l
 
c
a
n
c
e
r
H
e
L
a
 
(
a
d
e
n
o
c
а
r
-
c
i
n
o
m
a
)
p
-
g
l
y
c
o
p
r
o
-
t
e
i
n
4
Е
3
 
(
f
u
l
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centration required for staining and imaging of cell tar-
gets by an order of magnitude [89, 101]. These QDs are 
the most promising for use in the organism. However, 
it should be taken into consideration when designing 
them that QDs are not molecules but nanoparticles, 
and that the physicochemical properties of their sur-
face, rather than their composition, are more important 
factors in toxicity manifestation (the same is true for 
other nanoparticles). Some bioinert nanoparticles (gold, 
carbon) have the same toxic effect on cells as QDs. For 
example, gold nanoparticles and QDs coated with an 
amphiphilic polymer shell caused the same physical 
damages to a mammary cell culture and induced de-
tachment from the substrat [89]. Thus, although the 
additional, secondary stable shell prevents oxidation 
and degradation of a QD, it may itself contribute to the 
overall toxicity of the particles [102].
 In summary, it should be noted that since the ap-
pearance of the first colloidal QDs for biological appli-
cations, significant work has been carried out to reduce 
their toxicity, mainly by using various shells, and the 
groundwork has been laid for their in vivo application.
5.2 In vivo toxicity 
In vitro investigation of cytotoxicity is an important 
and necessary stage in the design of QD-based agents 
for diagnostics and therapy, since it allows accelerat-
ing and standartizing the process of selection of par-
ticles for in vivo application . However, these studies 
are usually insufficient for QD use in clinical practice. 
When using QDs for whole-body imaging, it is neces-
sary to take into account not only the colloidal nature 
and physicochemical properties of the surface of these 
particles, but also their interaction with the immune 
system and the possibility of physicochemical damage 
occurring under aggressive conditions in the organism, 
with the release of toxic elements from their fluores-
cent core.
To this point, data on the interaction between the 
immune system and certain types of nanoparticles (li-
posome, carbon, gold, magnetic) have been obtained 
[103]. After intravenous administration, nanoparticles 
were shown to become rapidly subjected to opsoniza-
tion and subsequent phagocytosis by the cells of the im-
mune system. Moreover, their injection into the blood 
may result in thrombocyte aggregation, activation of 
the complement system, and stimulation or suppres-
sion of the immune system [103]. With regard to QDs, 
there has been very little experimental data collected 
on this topic. It could be assumed that the interaction 
between QDs and the immune system cells is similar 
to the interaction that is typical of other nanoparticles. 
Indeed, it was shown by Japanese researchers [104] 
that QDs both in vitro and in vivo do not induce an in-
crease in cytokine production by CD4+ Т lymphocytes, 
but that they stimulate cell proliferation in the immune 
system.
The data obtained in the first systematic study of 
the toxicity and biodistribution of QDs in the organism 
were published quite recently [95]. Short-term (up to 7 
days) and long-term (more than 80 days) biological ef-
fects of QDs with different polymeric shells were stud-
ied in rat models. The standard clinical biochemical and 
hematological tests were carried out, as well as histo-
logical studies of organs. Contrary to expectations, after 
intravenous administration of QDs containing carboxyl 
groups, PEG, or bovine serum albumin on their surface 
(at a total dosage of 60 nmol/animal introduced within 
a period of four weeks), no pronounced toxicity was ob-
served for either particle variant.
The researchers studying QD biodistribution in the 
organism and the possibility of tumor imaging in vivo 
have also repeatedly observed the absence of indicators 
of acute toxicity in animals, the absence of necroses, 
and the retention of tissue morphology during experi-
ments [86, 93, 96]. However, the possibility of QD ac-
cumulation and degradation in the organism does not 
exclude their latent toxicity and delayed effect.
QD stability inside RES tissues and organs is the 
subject of intense debate. Some authors have dem -
onstrated that polymer-coated QDs retain their mor-
phology and fluorescent properties in tissues over a 
long period of time (up to 4 months) without degra -
dation and following the release of potentially toxic 
constituent elements of QDs [96, 97]. At the same time, 
the degradation of such particles in the organism, 
which results in fluorescence variation, was observed 
in some cases [53]. This process appears quite real, 
since it was shown in experiments in vitro that some 
ROS sources, such as oxygen peroxide and hypochlo-
rous acid, always present in the cell in small quanti-
ties, can pass through the polymeric shell and cause 
a degradation of the fluorescent core [105]. It is also 
possible that only a part of QDs is subjected to degra-
dation in the organism, while the other part remains 
intact; the ratio between these parts is just a matter of 
time (months or even years) [95].
Thus, no apparent toxicity of QDs in model organ-
isms has been shown. However, the existence of nu-
merous risk factors, insufficiency of data, and the ab-
sence of long-term studies prevents us from drawing a 
final conclusion on whether it is safe to use QDs in the 
organism. The separate, fragmentary and controversial 
data on QD toxicity found in studies devoted to the bio-
distribution of these particles emphasize the necessity 
of wide investigations that would deal with different 
systems of organs for an adequate assessment of the 
risks in the use of QDs in vivo.REVIEWS
 VOL. 3  № 1 (8)  2011  | ACTA NATURAE | 45
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Quantum dots are a relatively new class of compounds 
with seemingly immense potential for use in various 
types of tumor diagnostics, from the microplate assay 
for oncomarker detection to noninvasive in vivo im-
aging of tumors. The unique physicochemical proper-
ties of QDs, easily tunable fluorescence spectra, a high 
quantum yield (particularly, in the IR region), the pos-
sibility of excitation over a wide range of wavelengths 
and narrow emission fluorescence peaks, large section 
of two-photon absorption, and resistance to photob-
leaching, make possible a considerable broadening of 
the capabilities of  modern methods of fluorescence 
imaging and optical diagnostics. These fluorophores al-
low one to solve problems that are difficult to overcome 
using conventional dyes; e.g., simultaneous detection 
of several markers, long-term real-time observation 
of molecular processes, and taking images of tumors 
deep in tissues. However, when performing a number 
of routine tasks, the problems associated with the col-
loidal nature of QDs outweigh the advantages provided 
by their optical properties.
The relatively large surface area of QDs that is ac-
cessible for chemical modifications, coupled with the 
possibility of binding to other molecules and particles, 
allows to prepare various QD-based multimodule con-
structions that contain particles of different nature 
(gold,  magnet, diamond, liposome, etc.) in addition to 
the QDs (Fig. 3) [28, 106] and simultaneously possess 
targeting, diagnostic, and therapeutic properties [107]. 
These multifunctional nanodevices are intended for 
simultaneous delivery of an active agent to the tumor 
whilst monitoring this process [35, 62]. The further 
optimization of biocompatible QDs will facilitate the 
development of such innovative approaches in oncol-
ogy as image-guided surgery, molecular profiling of 
tumors, as well as personalized diagnostics and ther-
apy [108].
 The success of the realization of the high potential 
of the QD method and its implementation in in vivo di-
agnostics depends on achieving solutions to the follow-
ing important problems. The first such problem is the 
necessity of long-term toxicological studies and careful 
investigation of the delayed effect of QD introduction. 
Coatings based on polymeric materials have already 
been designed. They considerably enhance QD bioin-
ertness and appreciably reduced their toxicity. How-
ever, because QDs accumulate in reticuloendothelial 
system organs, their removal from the organism being 
very slow, how safe it is to use them in a living organ-
ism still requires further study.  In light of this, two 
other tasks can be formulated: firstly, the necessity to 
design a new generation of QDs that would be rapidly 
removed from the organism, and secondly the study of 
the effects of a possible introduction of QDs into the en-
vironment, whilst ensuring ecological safety upon wide 
application. Presumably, solving these tasks will lead to 
the development of new materials and technologies for 
constructing fluorescent nanoparticles. 
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